Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: A pilot study

Tsu F. Yeh, Hong C. Lin, Chien H. Chang, Tien S. Wu, Bai H. Su, Tsai C. Li, Suma Pyati, Chang H. Tsai

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

OBJECTIVE. Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects;it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality, and reduce chronic lung disease morbidity. PATIENTS AND METHODS. We conducted a prospective, randomized blind trial in 116 very low birth weight infants (<1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen >0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only, every 8 hours). The end point assessment was the number of infants who would die or develop chronic lung disease at 36 weeks' postconceptional age. RESULTS. Infants in the treatment group required significantly lower mean airway pressure on day 1 and day 3 and had significantly lower oxygen index and Pco 2 during the first 3 days than infants in the control group. More infants were extubated in the treatment group than controls at 1 and 2 weeks. The combined outcome of deaths or chronic lung disease was significantly lower in the treatment group than in the control group (19 of 60 vs 34 of 56). No clinically significant adverse effects were observed during the study. CONCLUSIONS. This pilot study indicated that early postnatal intratracheal instillation of budesonide using surfactant as vehicle significantly improved the combined outcome of death or chronic lung disease in small premature infants without causing immediate adverse effects. The results are encouraging, and a large sample multicenter trial is warranted.

Original languageEnglish
JournalPediatrics
Volume121
Issue number5
DOIs
Publication statusPublished - May 1 2008

Fingerprint

Budesonide
Premature Infants
Surface-Active Agents
Lung Diseases
Chronic Disease
Control Groups
Lung
Very Low Birth Weight Infant
Multicenter Studies
Therapeutics
Steroids
Parturition
Oxygen
Morbidity
Pressure
Mortality
beractant

Keywords

  • Budesonide
  • Chronic lung disease
  • Survanta

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants : A pilot study. / Yeh, Tsu F.; Lin, Hong C.; Chang, Chien H.; Wu, Tien S.; Su, Bai H.; Li, Tsai C.; Pyati, Suma; Tsai, Chang H.

In: Pediatrics, Vol. 121, No. 5, 01.05.2008.

Research output: Contribution to journalArticle

Yeh, Tsu F. ; Lin, Hong C. ; Chang, Chien H. ; Wu, Tien S. ; Su, Bai H. ; Li, Tsai C. ; Pyati, Suma ; Tsai, Chang H. / Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants : A pilot study. In: Pediatrics. 2008 ; Vol. 121, No. 5.
@article{6b44d9e2f3b641e382d56f839eb3ddb4,
title = "Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: A pilot study",
abstract = "OBJECTIVE. Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects;it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality, and reduce chronic lung disease morbidity. PATIENTS AND METHODS. We conducted a prospective, randomized blind trial in 116 very low birth weight infants (<1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen >0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only, every 8 hours). The end point assessment was the number of infants who would die or develop chronic lung disease at 36 weeks' postconceptional age. RESULTS. Infants in the treatment group required significantly lower mean airway pressure on day 1 and day 3 and had significantly lower oxygen index and Pco 2 during the first 3 days than infants in the control group. More infants were extubated in the treatment group than controls at 1 and 2 weeks. The combined outcome of deaths or chronic lung disease was significantly lower in the treatment group than in the control group (19 of 60 vs 34 of 56). No clinically significant adverse effects were observed during the study. CONCLUSIONS. This pilot study indicated that early postnatal intratracheal instillation of budesonide using surfactant as vehicle significantly improved the combined outcome of death or chronic lung disease in small premature infants without causing immediate adverse effects. The results are encouraging, and a large sample multicenter trial is warranted.",
keywords = "Budesonide, Chronic lung disease, Survanta",
author = "Yeh, {Tsu F.} and Lin, {Hong C.} and Chang, {Chien H.} and Wu, {Tien S.} and Su, {Bai H.} and Li, {Tsai C.} and Suma Pyati and Tsai, {Chang H.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1542/peds.2007-1973",
language = "English",
volume = "121",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants

T2 - A pilot study

AU - Yeh, Tsu F.

AU - Lin, Hong C.

AU - Chang, Chien H.

AU - Wu, Tien S.

AU - Su, Bai H.

AU - Li, Tsai C.

AU - Pyati, Suma

AU - Tsai, Chang H.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - OBJECTIVE. Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects;it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality, and reduce chronic lung disease morbidity. PATIENTS AND METHODS. We conducted a prospective, randomized blind trial in 116 very low birth weight infants (<1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen >0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only, every 8 hours). The end point assessment was the number of infants who would die or develop chronic lung disease at 36 weeks' postconceptional age. RESULTS. Infants in the treatment group required significantly lower mean airway pressure on day 1 and day 3 and had significantly lower oxygen index and Pco 2 during the first 3 days than infants in the control group. More infants were extubated in the treatment group than controls at 1 and 2 weeks. The combined outcome of deaths or chronic lung disease was significantly lower in the treatment group than in the control group (19 of 60 vs 34 of 56). No clinically significant adverse effects were observed during the study. CONCLUSIONS. This pilot study indicated that early postnatal intratracheal instillation of budesonide using surfactant as vehicle significantly improved the combined outcome of death or chronic lung disease in small premature infants without causing immediate adverse effects. The results are encouraging, and a large sample multicenter trial is warranted.

AB - OBJECTIVE. Budesonide is an inhaled steroid with a strong topical effect but with minimal systemic effects;it has been effectively delivered to animal lungs using surfactant as a vehicle. The purposes of this study were to determine whether early intratracheal instillation of budesonide using surfactant as a vehicle would improve pulmonary status, reduce mortality, and reduce chronic lung disease morbidity. PATIENTS AND METHODS. We conducted a prospective, randomized blind trial in 116 very low birth weight infants (<1500 g) who had severe radiographic respiratory distress syndrome and required mechanical ventilation with fraction of inspired oxygen >0.6 shortly after birth: 60 were in the treated group (intratracheal instillation of a mixture of 0.25 mg/kg of budesonide and 100.00 mg/kg of survanta, every 8 hours) and 56 were in the control group (100 mg/kg of survanta only, every 8 hours). The end point assessment was the number of infants who would die or develop chronic lung disease at 36 weeks' postconceptional age. RESULTS. Infants in the treatment group required significantly lower mean airway pressure on day 1 and day 3 and had significantly lower oxygen index and Pco 2 during the first 3 days than infants in the control group. More infants were extubated in the treatment group than controls at 1 and 2 weeks. The combined outcome of deaths or chronic lung disease was significantly lower in the treatment group than in the control group (19 of 60 vs 34 of 56). No clinically significant adverse effects were observed during the study. CONCLUSIONS. This pilot study indicated that early postnatal intratracheal instillation of budesonide using surfactant as vehicle significantly improved the combined outcome of death or chronic lung disease in small premature infants without causing immediate adverse effects. The results are encouraging, and a large sample multicenter trial is warranted.

KW - Budesonide

KW - Chronic lung disease

KW - Survanta

UR - http://www.scopus.com/inward/record.url?scp=44449106249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449106249&partnerID=8YFLogxK

U2 - 10.1542/peds.2007-1973

DO - 10.1542/peds.2007-1973

M3 - Article

C2 - 18426851

AN - SCOPUS:44449106249

VL - 121

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -